Oral deferiprone for iron chelation in people with thalassaemia

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2007, Pages

  Roberts, David J ^a   Brunskill, S J ^b   Doree, C ^b   Williams, S ^b   Howard, J ^b   Hyde, C J ^b  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b NONE

Author keywords

*Chelation therapy adverse effects ; Deferoxamine adverse effects; *therapeutic use ; Iron chelating agents adverse effects; *therapeutic use ; Iron overload *drug therapy ; Pyridones adverse effects; *therapeutic use

Indexed keywords

BIOCHEMICAL MARKER; DEFERIPRONE; DEFEROXAMINE; FERRITIN; PLACEBO;

ARTHRALGIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; EMBASE; FERRITIN BLOOD LEVEL; HUMAN; INJECTION PAIN; INJECTION SITE REACTION; IRON CHELATION; IRON OVERLOAD; IRON URINE LEVEL; LEUKOCYTE COUNT; LIVER FUNCTION TEST; MEDLINE; META ANALYSIS; NAUSEA; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCISEARCH; SIDE EFFECT; STOMACH DISCOMFORT; SYSTEMATIC REVIEW; THALASSEMIA MAJOR;

EID: 38349027353     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004839.pub2     Document Type: Review

References (115)

1. Aydinok 2005 {published data only} Aydinok Y, Evans P, Terzi A, Cetiner N, Porter JB. Randomised, prospective evaluation of iron balance, chelation efficiency, urine excretion and NTBI progression with deferiprone (DFP) or deferoxamine (DFO) monotherapy or with combined DFP plus DFO [abstract]. Blood 2005;106(11 Pt 1):2698.
2. Fassos 1994 {published data only} Fassos FF, Klein J, Fedrnandes D, Matsui D, Olivieri N, Koren G. Urinary iron excretion depends on the mode of administration of the oral iron chelator 1,2-dimethyl-3- hydroxypyrid-4-one in patients with homozygous beta-thalassaemia. Clinical Pharmacology and Therapeutics 1994;55(1):70-5.
3. Gomber 2004 {published data only} Gomber S, Saxena R, Mada N. Comparative efficacy of desferrioxamine, deferiprone and in combination on iron chelation in thalassaemic children. Indian Paediatrics 2004;4(1):21-7.
4. Ha (i) 2006 {published data only} Ha SY, Chik KW, Ling SC, Lee AC, Luk CW, Lam CW, et al.A randomised controlled study evaluating the safety and efficacy of deferiprone treatment in thalassaemia major patients from Hong Kong. Hemoglobin 2006;30(2):263-74.
5. Ha (ii) 2006 {published data only} Ha SY, Chik KW, Ling SC, Lee AC, Luk CW, Lam CW, et al.A randomised controlled study evaluating the safety and efficacy of deferiprone treatment in thalassaemia major patients from Hong Kong. Hemoglobin 2006;30(2):263-74.
6. Maggio 2002 {published data only} Galia M, Midiri M, Bartolotta V, Morabito A, Rizzo M, Mangiagli A, et al.Potential myocardial iron content evaluation by magnetic resonance imaging in thalassemia major patients treated with Deferoxamine or Deferiprone during a randomized multicenter prospective clinical study. Hemoglobin 2003;27(2):63-76.
7. Maggio A, Capra M, Ciaccio C, Magnano C, Rizzo M, Mangiagili A, et al.Evaluatrion of efficacy of LI versus desferrioaxamine by clinical randomised multicentric study [abstract]. Blood 1999;94(10 Suppl 1):34b.
8. *Maggio A, D'Amico G, Morabito A, Capra M, Ciaccio C, Cianciulli P, et al.Deferiprone versus deferoxamine in patients with thalassaemia major: a randomised clinical trial. Blood Cells, Molecules and Diseases 2002;28(2):196-208.
9. Mourad 2003 {published data only} Mourad FH, Hoffbrand, AV, Sheikah-Taha M, Koussa S, Khoriaty AI, Taher A. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overload thalassaemia patients. British Journal of Haematology 2003;121(1):187-9.
10. Olivieri 1990b {published data only} Olivieri NF, Kopren G, St Louis P, Freedman M, McClelland R, Templeton D. Studies of the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one in thalassaemia patients. Seminars in Haematology 1990;27(2):101-4.
11. *Olivieri NF, Koren G, Hermann C, Bentur Y, Chung D, Klein J, et al.Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients. Lancet 1990;336(8726):1275-9.
12. Olivieri NF, Koren G, Hermann C, Chung D, McClelland R, Freedman M, et al.Effective iron chelation with L1 in patients with thalassemia major: iron balance and dose response studies [abstract]. Blood 1989;174(7 Suppl 1):51a.
13. Olivieri NF, Templeton DM, Koren G, Chung D, Herman C, Freedman MH, et al.Evaluation of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients. Annals of the New York Academy of Sciences 1990;612:369-77.
14. Olivieri 1997 {published data only} Hackman R, Berkovitch M, Sher G, Brittenham G, Koren G, Olivieri N. Studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in patients with beta- haemoglobinopathies: The Canadian trial [abstract]. 25th Congress of the International Society of Hematology; 1994 April 17 -21. 1994:213.
15. Olivieri N and The Iron Chelation Research Group. Randomized trial of deferiprone (LI) and deferoxamine (DFO) in thalassemia major [abstract]. Blood 1996;10(Suppl 1):651a.
16. Olivieri NF, Brittenham GM. Evidence of progression of myocardial iron loading as determinede by magnetic resonance imaging (MRI) in thalassaemia patients during treatment with deferiprone (L1) and deferoxamine (DFO) [abstract]. Blood 1999;94(10 Suppl 1):35b.
17. *Olivieri NF, Brittenham GM. Final results of the randomised trial of deferiprone (L1) and deferoxamine (DFO) [abstract]. Blood 1997;90:264a.
18. Olivieri NF, Brittenham GM. Armstrong SAM, Basran RK, Daneman R, Daneman N, et al.First prospective randomised trrial oif the iron chelators (L1) and deferoxamine [abstract]. Blood 1995;86(10 Suppl 1):249a.
19. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, et al.Survival inmedically treated patients with homozygous beta-thalassemia. New England Journal of Medicine 1994;331(9):574-8.
20. Pope E, Berkovitch M, Olivieri N, Koren G. First prospective randomized trial of subcutaneous deferoxamineand the orally active chelating agent L1. 96th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 1995 March 15-17; San Diego. 1995; Vol. World Meeting Number 951 0002.
21. Pennell 2006 {published data only} Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessops A, et al.Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006;107(9):3738-44.
22. A-Metaxa 2004 Athanassiou-Metaxa M, Kousi A, Hatzipantelis E, Tsatra I, Ikonomou M, Perifanis V, et al.Combined chelation therapy with deferiprone and desferrioxamine in iron overloaded β-thalassemia patients. Haematologica 2004; Vol. 89, issue 3:ELT07.
23. al Refaie 1992 Al-Refaie FN, Wickens DG, Wonke B, Kontoghiorghes GJ, Hoffbrand AV. Serum non-transferrin-bound iron in beta-thalassaemia major patients treated with desferrioxamine and L1. British Journal of Haematology 1992;82(2):431-6.
24. Anderson 2002 Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 2002;360(9332):516-20.
25. Athanassiou 2003 Athanassiou MM, Tzimouli V, Economou M, Taparkou A, Tourkantoni N, Kanakoudi TF. Immune status of thalassemic patients receiving deferiprone or combined deferiprone and desferrioxamine chelation treatment (2). Acta Haematologica 2003;110(4):224-6.
26. Bartfay 1999 Bartfay WJ, Lehotay DC, Sher GD, Bartfay E, Tyler B, Luo X, et al.Erythropoiesis: comparison of cytotoxic aldehyde generation in beta-thalassaemia patients chelated with deferoxamine or deferiprone (L1) versus no chelation. Haematology 1999;4(1):67-76.
27. Cohen 1997 Cohen A, Galanello R, Piga A, Vullo C. A Multi-Center Safety Trial of the Oral Iron Chelator Deferiprone. Annals of the New York Academy of Sciences 1998;850:223-6.
28. Diav-Citrin 1997 Diav-Citrin O, Atanackovic G, Loebstein R, Koren G. Investigation of variability in response to deferiprone (L1) inpatients with beta-thalassemia major [abstract]. 98th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 1997 March 5-8; San Diego. 1997.
29. Galanello 2001 Galanello R, Doneddu I, Dessi C, Defraia E, Dolci C, Leoni G, et al.Iron chelation in thalassemiamajor: Combined treatment with deferiprone (DFP) and desferrioxamine (DFO) [abstract]. BIO IRON World Congress on Iron Metabolism; 2001 August 18-23; Cairns. 2001:P78.
30. Hershko 1996 Hershko C, Hoffbrand A, Olivieri N, Al-Refaie F, Tondury P, Wonke B. International study group on oral iron chelators: Results of long-term deferiprone (LI) therapy [abstract]. 2nd Meeting of the European Haematology Association; 1996 29 May - 1 June; Paris. 1996:570.
31. Kontoghiorghes 1987 Kontoghiorghes GJ, Aldouri MA, Hoffbrand AV, Barr J, Wonke B, Kourouclaris T, et al.Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one. British Medical Journal 1987;295(6612):1509-12.
32. Loebstein 1997 Loebstein R, Dalal I, Nisbet-Brown E, Berkovitch M, Meydan N, Andrews D, et al.Immune function in patients with beta-thalassamia receiving the orally active iron-chelating agent deferiprone. British Journal of Haematology 1997;98(3):597-600.
33. Marshall 2003 Marshall R, Tricta F, Galanello R, Leoni G, Kirkland D, Minto S, et al.Chromosomal aberration frequencies in patients with thalassaemia major undergoing therapy with deferiprone and deferoxamine in a comparative crossover study. Mutagenesis 2003;18(5):457-63.
34. Nielsen 1995 Nielsen P, Fischer R, Engelhardt R, Tondury P, Gabbe EE, Janka GE. Liver iron stores in patients with secondary haemosiderosis under iron chelation therapy with deferoxamine or deferiprone. British Journal of Haematology 1995;91(4):827-33.
35. Olivieiri 1993 Olivieri N, Brittenham G, Koren G. Reduction in hepatic iron stores with the oral iron chelator L1 inpatients with transfusion-dependent thalassemia and sickle cell disease: First three years of the Canadian trial [abstract]. 35th Annual Meeting and Exposition of the American Society of Hematology; 1993 December 3-7; St. Louis. 1993:1238.
36. Peng 2003 Peng CT, Chow KC, Chen JH, Chiang YP, Lin TY, Tsai CH. Safety monitoring of cardiac and hepatic systems in beta-thalassemia patients with chelating treatment in Taiwan. European Journal of Haematology 2003;70(6):392-7.
37. Pepe 2006 Pepe A, Lombardi M, Positano V, Cracolici E, Capra M, Malizia R, et al.Evaluation of the efficacy of oral deferiprone in beta-thalassaemia major by multislice multiecho T2*. European Journal of Haematology 2006;76(3):183-92.
38. St Pierre 2003 St Pierre TG. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility. Lancet 2003;361(9352):182.
39. Taher 2001 Taher A, Sheikh-Taha M, Koussa S, Inati A, Neeman R, Mourad F. Comparison between deferoxamine and deferirpone (L1) in iron-loaded patients. European Journal of Haematology 2001;67(1):30-4.
40. Choudhry 2004 Choudhry VP, Pati HP, Saxena A, Malaviya AN. Deferiprone, efficacy and safety. Indian Journal of Paediatrics 2004;71(3):213-6.
41. Galanello 2004 Galanello R, Kattamis A, Piga A, Tricta F. Safety and efficacy of alternate desferrioxamine and deferiprone compared to desferrioxamine alone in the treatment of iron overload in transfusion-dependent thalassemia patients [abstract]. Blood 2004;104(11 Pt 1):Abst 3611.
42. Grady 1996 Grady RW, Hilgartner MW, Giardina PJ. Deferiprone: its efficacy relative to that of desferal [abstract]. Blood 1996;88(10):310a.
43. Grady 2002 Grady RW, Berdoukas VA, Rachmilewitz EA, Galanello R, Borgna-Pignatti C, Ladis V, et al.Combinations of desferrioxamine and deferiprone markedly enhance iron excretion [abstract]. Blood 2002;100:241a.
44. Tanner 2005 Tanner MA, Galanello R, Dessi C, Westwood MA, Smith GC, Khan M, et al.A randomized, placebo controlled double blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassaemia major using cardiovascular magnetic resonance [abstract]. Blood 2005; Vol. 106, issue 11 Pt 1:Abst 3655.
45. NCT00115349 NCT00115349. Combination therapy compared with single-drug therapy in patients with cardiac diseases. National Heart, Lung and Blood Institute Trial started June 2005: currently ongoing.
46. Agarwal 1992 Agarwal MB, Gupte SS, Viswanathan C, Vasandani D, Ramanathan J, Desai N, et al.Long term assessment of efficacy and safety of L1, an oral iron chelator in transfusion-dependent thalassaemia: Indian trial. British Journal of Haematology 1992;82(2):460-6.
47. Aldouri 1990 Aldouri MA, Wonke B, Hoffbrand AV, Flynn DM, Ward SE, Agnew JE, et al.High incidence of cardiomyopathy in beta-thalassaemia patients receiving transfusion and iron chelation: reversal by intensified chelation. Acta Haematologica 1990;84(3):113-7.
48. Bacon 1983 Bacon BR, Tavil AS, Brittenham GM, Park CH, Recknagel RO. Hepatic lipid peroxidation in vivo in rats with chronic iron overload. Journal of Clinical Investigation 1983;71(3):429-39.
49. Berdoukas 2000 Berdoukas V, Bohane T, Eagle C, Lindeman R, DeSilva K, Tobias V, et al.The Sydney Children's Hospital experience with the oral iron chelator deferiprone (L1). Transfusion Science 2000;23(3):239-40.
50. Borgna-Pignatti 1998 Borgna-Pignatti C, Rugolotto S, De Stefano P, Piga A, Di Gregorio F, Gamberini MR, et al.Survival and disease complications in thalassemia major. Annals of the New York Academy of Sciences 1998;850:227-31.
51. Borgna-Pignatti 2004 Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, et al.Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004;89(10):1187-93.
52. Brittenham 1994 Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, et al.Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. New England Journal of Medicine 1994;331(9):567-73.
53. Brittenham 2003 Brittenham GM, Nathan DG, Olivieri NF, Porter JB, Pippard M, Vichinsky EP, et al.Deferiprone and hepatic fibrosis. Blood 2003;101(12):5089-90.
54. Cappellini 2006 Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, et al.A phase 3 study of deferasirox (ICL670), a once daily oral iron chelator, in patients with beta-thalassemia. Blood 2006;107(9):3455-62.
55. Caro 2002 Caro JJ, Huybrechts KF, Green TC. Estimates of the effect on hepatic iron of oral deferiprone compared with subcutaneous desferrioxamine for treatment of iron overload in thalassaemia major: a systematic review. http://www.biomedcentral.com/1471-2326/2/4 2002 (accessed 21 May 2007); Vol. 2, issue 4.
56. Ceci 2002 Ceci A, Felisi M, Catapano M, Baiardi P, Cipollina L, Ravera S, et al.The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. British Journal of Haematology 2002;118(1):330-6.
57. Cohen 2003 Cohen AR, Galanello R, Piga A, DeSanctis V, Tricta F. Safety and effectiveness of long term therapy with the oral iron chelator deferiprone profile of the oral iron chelator: a multicentre study. Blood 2003;102(5):1583-7.
58. Davies 1983 Davies SC, Marcus RE, Hungerford JL, Miller MH, Arden GB, Huehns ER. Ocular toxicity of high-dose intravenous desferrioxamine. Lancet 1983;23(2):181-4.
59. Del Vecchio 2000 Del Vecchio GC, Crollo E, Schettini F, Fischer R, De Mattia D. Factors influencing effectiveness of deferiprone in a thalassaemia major clinical setting. Acta Haematologica 2000;104(2-3):99-102.
60. Ehlers 1991 Ehlers KH, Giardina PJ, Leser ML, Engle MA, Hilgartner MW. Prolonged survival in patients with beta-thalassemia major treated with desferrioxamine. Journal of Paediatrics 1991;118(4 Pt 1):540-5.
61. Elbourne 2002 Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analysis involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
62. Fischer 2003 Fischer R, Longo F, Nielsen P, Engelhardt R, Hider RC, Piga A. Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with thalassaemia major: applicability of SQUID biomagnetic liver susceptometry. British Journal of Haematology 2003;121(6):938-48.
63. Gabutti 1996 Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematologica 1996;95(1):26-36.
64. Galia 2003 Galia M, Midiri M, Bartolotta V, Morabito A, Rizzo M, Mangiagli A, et al.Potential myocardial iron content evaluation by magnetic resonance imaging in thalassemia major patients treated with Deferoxamine or Deferiprone during a randomized multicenter prospective clinical study. Hemoglobin 2003;27(2):63-76.
65. Gallant 1986 Gallant T, Freedman MH, Vellend H, Francombe WH. Yersinia sepsis in patients with iron overload treated with deferoxamine. New England Journal of Medicine 1986;314(25):1643.
66. Hackman 1994 Hackman R, Berkovitch M, Sher G, Brittenham G, Koren G, Olivieri N. Studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4- one (L1) in patients with beta-haemoglobinopathies: The Canadian trial. 25th Congress of the International Society of Hematology. 1994 17 -21 Apr. 1994.
67. Henter 2007 Henter JI, Karlen J. Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemia. Blood 2007;Mar 7:Epub ahead of print.
68. Hider 1984 Hider RC, Kontoghiorghes G, Silver J, Stockham MA. Pharmaceutically active hydroxypyridones. GB patent 21-46989 1984.
69. Higgins 2006 Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]. In: The Cochrane Library Issue 4, 2006. Chichester, UK: John Wiley & Sons Ltd.
70. Hoffbrand 1998 Hoffbrand AV, Al-Refaie F, Davis B, Siritanakatkul N, Jackson BF, Cochrane J, et al.Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood 1998;91(1):295-300.
71. Jüni 2001 Jüni P, Altman DG, Egger M. Systematic Reviews in Health Care: Assessing the quality of controlled clinical trials. BMJ 2001;323(7303):42-6.
72. Kontoghiorghes 1990 Kontoghiorghes GJ, Bartlett AN, Hoffbrand AV, Goddard JG, Sheppard L, Barr J, et al.Long term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-1 (L1), I: iron chelation and metabolic studies. British Journal of Haematology 1990;76(2):295-300.
73. Kontzogolou 1996 Kontzoglou G, Koussi A, Tsatra J, Noussios G, Vital V, Sagarakis G, et al.Sensorineural hearing loss in children with thalassemia major in Northern Greece. International Journal of Pediatric Otorhinolaryngology 1996;35(3):223-30.
74. Kushner 2001 Kushner JP, Porter JP, Olivieri NF. Secondary iron overload. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2001;1:47-61.
75. Lucas 2002 Lucas GN, Perera BJ, Fonseka EA, Silva DD, Fernandopulle M, Karunatilaka DH, et al.Experience with the oral iron chelator deferiprone in transfusion-dependent children. Ceylon Medical Journal 2002;47(4):119-21.
76. Maggio 1999 Maggio A, Capra M, Ciaccio C, Magnano C, Rizzo M, Mangiagli A, et al.Evaluation of efficacy of L1 versus desferrioxamine by clinical randomized multicentric study [abstract]. Blood 1999;10(Supp 1 (Pt 2)):34b.
77. Mazza 1998 Mazza P, Amurri B, Lazzari G, Masi C, Palazzo G, Spartera MA, et al.Oral iron chelating therapy. A single center interim report on deferiprone (L1) in thalassemia. Haematologica 1998;83(6):496- 501.
78. Modell 2000 Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 2000;355(9220):2051-2.
79. Nathan 2002 Nathan DG, Weatherall DJ. Academic freedom in clinical research. New England Journal of Medicine 2002;347(17):1368-71.
80. Neufeld 2006 Neufeld EJ. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood 2006;107(9):3436-41.
81. Olivieri 1986 Olivieri NF, Buncic R, Chew E, Gallant T, Harrison RV, Keenan N, et al.Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. New England Journal of Medicine 1986;314(14):869-73.
82. Olivieri 1989 Olivieri NF, Koren G, Hermann C, Chung D, McClelland R, Freedman M, et al.Effective iron chelation with L1 in patients with thalassemia major: iron balance and dose response studies [abstract]. Blood 1989;74(7, Suppl 1):51a.
83. Olivieri 1990 Olivieri NF, Koren G, St Louis P, Freedman MH, McClelland RA, Templeton DM. Studies of the oral chelator 1,2-dimethyl-3- hydroxypyrid-4-one in thalassemia patients. Seminars in Hematology 1990;27(2):101-4.
84. Olivieri 1990a Olivieri NF, Templeton DM, Koren G, Chung D, Hermann C, Freedman MH, et al.Evaluation of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one [L1) in iron-loaded patients. Annals of the New York Academy of Sciences 1990; Vol. 612:369-77.
85. Olivieri 1992 Olivieri NF, Koren G, Matsui D, Liu PP, Blendis L, Cameron R, et al.Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia. Blood 1992;79(10):2741-8.
86. Olivieri 1994 Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, et al.Survival in medically treated patients with homozygous beta-thalassemia. New England Journal of Medicine 1994;331(9):574- 8.
87. Olivieri 1994a Olivieri NF, Sher GD, MacKinnon JA, Pope I, Entsuah B, Snider MA, et al.The first prospective randomized trial of subcutaneous deferoxamine and the orally active iron chelating agent L1 [abstract]. Blood 1994;84(Suppl 1):363a.
88. Olivieri 1995a Olivieri NF, Brittenham GM, Armstrong SAM, Barsran RK, Daneman R, Daneman N, et al.First prospective randomized trial of the iron chelators deferiprone and deferoxamine [abstract]. Blood 1995;86(Suppl 1):249a.
89. Olivieri 1995b Olivieri NF, Brittenham GM, Matsui D, Berkovitch M, Blendis LM, Cameron RG, et al.Iron-chelation therapy with oral deferiprone in patients with thalassemia major. New England Journal of Medicine 1995;332(14):918-22.
90. Olivieri 1996 Olivieri N and The Iron Chelation Research Group. Randomized trial of deferiprone (LI) and deferoxamine (DFO) in thalassemia major [abstract]. Blood 1996; Vol. 10, issue Suppl 1:651a.
91. Olivieri 1997a Olivieri NF, Brittenham GM. Final results of the randomized trial of deferiprone (L1) and deferoxamine (DFO) [abstract]. Blood 1997;90(Suppl 1):264a.
92. Olivieri 1997b Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997;89(3):739-61.
93. Olivieri 1998 Olivieri N, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McClelland RA, et al.Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. New England Journal of Medicine 1998;339(7):417-23.
94. Olivieri 1999 Olivieri NF. The beta-thalassemias. New England Journal of Medicine 1999;341(2):99-109.
95. Olivieri 1999a Olivieri NF, Brittenham GM. Evidence of progression of myocardial iron loading as determined by magnetic resonance imaging (MRI) in thalassemia patients during treatment with deferiprone (L1) and deferoxamine (DFO) [abstract]. Blood 1999; Vol. 10, issue Suppl. 1 (Part 2 of 2):35b.
96. Pati 1999 Pati HP, Choudry VP. Deferiprone (L1) associated neutropenia in beta thalassaemia major: an Indian experience. European Journal of Haematology 1999;63(4):267-8.
97. Piga 1988 Piga A, Luzzatto L, Capalbo P, Gambotto S, Tricta F, Gabutti V. High dose desferrioxamine as a cause of growth failure in thalassaemic patients. European Journal of Haematology 1988;40(4):380-1.
98. Pippard 1978 Pippard MJ, Letsky EA, Callender ST, Weatherall DJ. Prevention of iron loading in transfusion-dependent thalassaemia. Lancet 1978;1(8075):1178-81.
99. Pope 1995 Pope E, Berkovitch M, Olivieri N, Koren G. First prospective randomized trial of subcutaneous deferoxamine and the orally active chelating agent L1 [abstract]. Proceedings of the 96th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; 1995 March 15-17; San Diego. 1995.
100. Porter 1989a Porter J, Huehns E. The toxic effects of desferrioxamine. Balliere's Clinical Haematology 1989;2(2):459-74.
101. Porter 1989b Porter JB, Jawson MS, Huehns ER, East CA, Hazell JWP. Desferrioxamine ototoxicity: evaluation of risk factors in thalassamic patients and guidelines for safe dosage. British Journal of Haematology 1989;73(3):403-9.
102. Porter 2002 Porter J, Davis BA. Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia. Best Practice Research in Clinical Haematology 2002;15(2):329-68.
103. Propper 1976 Propper RD, Shurin SB, Nathan DG. Reassessment of the use of desferrioxamine B in iron overload. New England Journal of Medicine 1976;294(26):1421-3.
104. Propper 1977 Propper RD, Cooper B, Rufo RR, Nienhuis AW, Anderson WF, Bunn HF, et al.Continuous subcutaneous administration of deferoxamine in patients with iron overload. New England Journal of Medicine 1977;297(8):418-23.
105. Review Manager 2003 The Cochrane Collaboration. Review Manager (RevMan). 4.2.3 for Windows. Oxford, England: The Cochrane Collaboration, 2003.
106. Richardson 1993 Richardson ME, Matthews RN, Alison JF, Menahem S, Mitvalsky J, Byrt E, et al.Prevention of heart disease by subcutaneous desferrioxamine in patients with thalassaemia major. Australian and New Zealand Journal of Medicine 1993;23(6):656-61.
107. Roberts 2004 Roberts DJ, Rees D, Howard J, Hyde C, Brunskill S. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia (Cochrane Review). Cochrane Database of Systematic Reviews 2005, Issue 4.Art. No.: CD004450. DOI:10.1002/14651858. CD004450.pub2.
108. Rombos 2000 Rombos Y, Tzanetea R, Konstantopoulos K, Simitizis S, Zervas C, Kyriaki P, et al.Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1). Haematologica 2000;85(2):115-7.
109. Swedish Orphan Drug Swedish Orphan Drug International AB. Ferriprox (Deferiprone) Summary of Product Charcteristics. www.Swedishorphan.com (accessed 2007).
110. Tondury 1990 Tondury P, Kontoghiorghes GJ, Ridolfi-Luthy A, Hirt A, Hoffbrand AV, Lottenbach AM, et al.L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with beta-thalassaemia major. British Journal of Haematology 1990;76(4):550-3.
111. Tondury 1998 Tondury P, Zimmermann A, Nielsen P, Hirt A. Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients. British Journal of Haematology 1998;101(3):413-5.
112. Viens 2004 Viens AM, Savulescu J. Introduction to the Olivieri symposium. Journal of Medical Ethics 2004;30(1):1-7.
113. Wanless 2002 Wanless IR, Sweeney G, Dhillon AP, Guido M, Piga A, Galanello R, et al.Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood 2002;100(5):1566-9.
114. Weatherall 2002 Weatherall DJ, Clegg JB. The Thalassaemia Syndromes. 4th Edition. Oxford: Blackwell Science, 2002.
115. Wolfe 1985 Wolfe L, Olivieri N, Sallan D, Colan S, Rose V, Propper R, et al.Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. New England Journal of Medicine 1985;312(25):1600-3.